Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TLR8 | Q9NR97 | 6/20 | 0.49 |
| ▸ | TLR7 | Q9NYK1 | 6/20 | 0.49 |
| ▸ | CDK1 | P06493 | 1/20 | 0.41 |
| ▸ | CDK2 | P24941 | 1/20 | 0.41 |
| ▸ | FTO | Q9C0B1 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.38 |
| ▸ | TLR9 | Q9NR96 | 4/20 | 0.38 |
| ▸ | HPGD | P15428 | 3/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.38 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.38 |
| ▸ | KIF11 | P52732 | 2/20 | 0.38 |
| ▸ | RAB9A | P51151 | 2/20 | 0.37 |
| ▸ | MEN1 | O00255 | 2/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.37 |
| ▸ | HCRTR1 | O43613 | 1/20 | 0.37 |
| ▸ | MAPT | P10636 | 1/20 | 0.37 |
| ▸ | NPC1 | O15118 | 1/20 | 0.36 |
| ▸ | FYN | P06241 | 1/20 | 0.36 |
| ▸ | THRB | P10828 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3462210 | 0.84 | KDM4E (0.53) | FTOALDH1A1HPGDKDM4EKIF11 | |
| SCHEMBL3207259 | 0.81 | KDM4E (0.45) | TLR8TLR7CDK1CDK2ALDH1A1 | |
| SCHEMBL3205039 | 0.81 | TLR8 (0.53) | TLR8TLR7CDK1CDK2ALDH1A1 | |
| SCHEMBL3460950 | 0.80 | TLR8 (0.50) | TLR8TLR7ALDH1A1TLR9HPGD | |
| Butane SCHEMBL17912768 | 0.80 | KDM4E (0.48) | ALDH1A1HPGDSMN1; SMN2KDM4EKIF11 | |
| Sr-13668 SCHEMBL1071997 | 0.78 | KDM4E (0.64) | CDK1CDK2ALDH1A1HPGDSMN1; SMN2 | |
| Sr-13668 SCHEMBL30173443 | 0.78 | KDM4E (0.64) | CDK1CDK2ALDH1A1HPGDSMN1; SMN2 | |
| Sr-13668 SCHEMBL29381258 | 0.78 | KDM4E (0.64) | CDK1CDK2ALDH1A1HPGDSMN1; SMN2 | |
| SCHEMBL12813715 | 0.78 | ALDH1A1 (0.57) | TLR8TLR7ALDH1A1TLR9HPGD | |
| SCHEMBL12642105 | 0.75 | KDM4E (0.58) | CDK2ALDH1A1HPGDSMN1; SMN2KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2694057-B1 | LIPOXYGENASE INHIBITORS | STANFORD RES INST INT (US) | 2019-06-05 | — | — | EP | claimed |
| US-10646471-B2 | Lipoxygenase inhibitors | SRI INTERNATIONAL (US) | 2020-05-12 | — | — | US | disclosed |
| EP-2694057-B1 | LIPOXYGENASE INHIBITORS | STANFORD RES INST INT (US) | 2019-06-05 | — | — | EP | disclosed |
| US-20170095450-A1 | Lipoxygenase Inhibitors | SRI INTERNATIONAL | 2017-04-06 | — | — | US | disclosed |
| EP-2694057-A1 | LIPOXYGENASE INHIBITORS | SRI International (US) | 2014-02-12 | — | — | EP | disclosed |
| US-20130345214-A1 | Lipoxygenase Inhibitors | SRI INTERNATIONAL, INC. (US) | 2013-12-26 | — | — | US | disclosed |
| WO-2012135133-A1 | LIPOXYGENASE INHIBITORS | SRI INTERNATIONAL (US) | 2012-10-04 | — | — | WO | disclosed |
| US-20120184590-A1 | FORMULATIONS OF INDOLE-3-CARBINOL DERIVED ANTITUMOR AGENTS WITH INCREASED ORAL BIOAVAILABILITY | UNIVERSITY OF KANSAS (US) | 2012-07-19 | — | — | US | disclosed |
| WO-2010118339-A2 | FORMULATIONS OF INDOLE-3-CARBINOL DERIVED ANTITUMOR AGENTS WITH INCREASED ORAL BIOAVAILABILITY | UNIVERSITY OF KANSAS (US) | 2010-10-14 | — | — | WO | disclosed |
| US-7666897-B2 | Analogs of indole-3-carbinol metabolites as chemotherapeutic and chemopreventive agents | SRI INTERNATIONAL (US) | 2010-02-23 | — | — | US | disclosed |
| US-20090023796-A1 | Analogs of Indole-3-Carbinol Metabolites as Chemotherapeutic and Chemopreventive Agents | SRI INTERNATIONAL (US) | 2009-01-22 | — | — | US | disclosed |
| EP-1530572-B1 | ANALOGS OF INDOLE-3-CARBINOL METABOLITES AS CHEMOTHERAPEUTIC AND CHEMOPREVENTIVE AGENTS | STANFORD RES INST INT (US) | 2008-10-15 | — | — | EP | disclosed |
| US-7429610-B2 | Analogs of indole-3-carbinol metabolites as chemotherapeutic and chemopreventive agents | SRI INTERNATIONAL (US) | 2008-09-30 | — | — | US | disclosed |
| US-7078427-B2 | Analogs of indole-3-carbinol metabolites as chemotherapeutic and chemopreventive agents | SRI INTERNATIONAL (US) | 2006-07-18 | — | — | US | disclosed |
| EP-1623985-A2 | Analogs of indole-3-carbinol metabolites as chemotherapeutic and chemopreventative agents | Sri International (US) | 2006-02-08 | — | — | EP | disclosed |
| EP-1530572-A2 | ANALOGS OF INDOLE-3-CARBINOL METABOLITES AS CHEMOTHERAPEUTIC AND CHEMOPREVENTIVE AGENTS | Sri International (US) | 2005-05-18 | — | — | EP | disclosed |
| US-6800655-B2 | Analogs of indole-3-carbinol metabolites as chemotherapeutic and chemopreventive agents | SRI INTERNATIONAL | 2004-10-05 | — | — | US | disclosed |
| US-20040157906-A1 | Analogs of indole-3-carbinol metabolites as chemotherapeutic and chemopreventive agents | JONG LING (US) | 2004-08-12 | — | — | US | disclosed |
| WO-2004018475-A2 | ANALOGS OF INDOLE-3-CARBINOL METABOLITES AS CHEMOTHERAPEUTIC AND CHEMOPREVENTIVE AGENTS | SRI INTERNATIONAL (US) | 2004-03-04 | — | — | WO | disclosed |
| US-20040043965-A1 | Analogs of indole-3-carbinol metabolites as chemotherapeutic and chemopreventive agents | SRI INTERNATIONAL | 2004-03-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170095450-A1 | Lipoxygenase Inhibitors | ALOX15B, ALOX12, ALOX15 | TLR8 3602/4885TLR7 4638/4885CDK1 1775/4885 |
| US-20120184590-A1 | FORMULATIONS OF INDOLE-3-CARBINOL DERIVED ANTITUMOR AGENTS WITH INCREASED ORAL BIOAVAILABILITY | SCD, SCD5, IDO1 | TLR8 373/4885TLR7 665/4885CDK1 1534/4885 |
| US-20130345214-A1 | Lipoxygenase Inhibitors | ALOX15B, ALOX12, ALOX15 | TLR8 3602/4885TLR7 4638/4885CDK1 1775/4885 |
| US-10646471-B2 | Lipoxygenase inhibitors | ALOX15B, ALOX12, ALOX15 | TLR8 3602/4885TLR7 4638/4885CDK1 1775/4885 |
| US-20090023796-A1 | Analogs of Indole-3-Carbinol Metabolites as Chemotherapeutic and Chemopreventive Agents | IDO1, CCND3, CCNA1 | TLR8 2773/4885TLR7 2377/4885CDK1 208/4885 |
| US-20040043965-A1 | Analogs of indole-3-carbinol metabolites as chemotherapeutic and chemopreventive agents | IDO1, IDO2, TPH1 | TLR8 1999/4885TLR7 2325/4885CDK1 257/4885 |
| US-20040157906-A1 | Analogs of indole-3-carbinol metabolites as chemotherapeutic and chemopreventive agents | IDO1, IDO2, TPH1 | TLR8 1999/4885TLR7 2325/4885CDK1 257/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.